At the World Glaucoma Congress (WGC) in Rome, Italy this summer, Ciliatech presented preliminary results of the second 2-year postoperative clinical trial (SAFARI Ⅱ) on its Cilioscleral Interposition Device (CID).
Glaucoma is a group of progressive, neurodegenerative eye diseases associated with irreversible optic neuropathy followed by visual-field impairment. Epidemiological estimates suggest that the most common form,
Ciliatech reports positive clinical results on novel glaucoma implant, CID, in 24-month post-operative
follow-up. Data support sustained safety and performance of first generation glaucoma implant CID (Cilio-scleral Interpositioning Device)...
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.